Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Jacobio Pharma Announces Strategic Partnership with Oceanpine Capital to Focus on Core Oncology Pipeline 2025-10-15 23:05
Jacobio Chairman and Concerted Parties Increase Shareholding by Nearly HK$100 Million, Demonstrating Confidence in Long-term Growth 2025-09-26 08:47
Jacobio Pharma Announces 2025 Interim Results 2025-08-30 00:25
Jacobio Pharma Announces 2024 Annual Results 2025-03-19 21:42
The Registrational Clinical Data of Glecirasib was Published in Nature Medicine 2025-01-07 08:30
Jacobio Pharma Presented preliminary Data on BET Inhibitor for Myelofibrosis at 2024 ASH 2024-12-09 08:42
Jacobio Out-licensed KRAS G12C Inhibitor Glecirasib and SHP2 Inhibitor JAB-3312 to Allist in China 2024-08-30 19:34
Jacobio Pharma Presents SHP2 Plus KRAS G12C Data at ASCO 2024-06-02 08:25
Jacobio Pharma Announced its KRAS G12C inhibitor reached the primary endpoint 2024-05-01 08:59
Jacobio Pharma to Present Data of PARP7 Inhibitor and P53 Reactivator at the 2024 AACR Annual Meeting 2024-04-09 19:59
Jacobio Pharma Announces 2023 Annual Results 2024-03-29 08:50
Jacobio Pharma Receives IND Approval for P53 Y220C Activator JAB-30300 in the U.S. 2024-03-01 14:55
Jacobio Announces China CDE Clearance for Phase III Clinical Trial of SHP2 Inhibitor Plus KRAS G12C Inhibitor 2024-02-18 20:50
Jacobio Pharma Presents Data of Glecirasib in Patients with Pancreatic Cancer and Other Solid Tumors at the 2024 ASCO GI 2024-01-20 06:30
Jacobio Pharma Presents Clinical Results of Glecirasib in Combination with JAB-3312 at ESMO 2023-10-22 15:05
Jacobio Pharma Announces 2023 Interim Results 2023-08-30 21:45
Jacobio Pharma Announces Breakthrough Therapy Designation from China CDE for KRAS G12C Inhibitor Glecirasib for the Treatment of Pancreatic Cancer 2023-08-07 20:03
Jacobio Pharma to Present Data of Glecirasib in Combination with JAB-3312 at the 2023 ESMO Conference 2023-07-21 10:19
Jacobio Receives CDE Approval for Glecirasib's Pancreatic Cancer Pivotal Study in China 2023-07-04 21:16
Jacobio Pharma Presents Clinical Results of Glecirasib in Colorectal Cancer 2023-06-29 16:31
1 2 3